Drug Trial Radar · NCT00454480
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Last checked: Nov 19, 2026Latest source record: Aug 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Planned (sponsor's estimate)
Start
Aug 2006
Primary completion
Aug 2012
Sponsor
- Lead sponsor
- The University of New South WalesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with gemtuzumab ozogamicin or tipifarnib may kill more cancer cells. PURPOSE: This randomized phase II/III trial is studying different combination chemotherapy regimens to compare how well they work when given with or without gemtuzumab ozogamicin or tipifarnib in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Conditions
- Leukemia
- Myelodysplastic Syndromes
Interventions
alemtuzumabBiological
arsenic trioxideDrug
azacitidineDrug
busulfanDrug
clofarabineDrug
cytarabineDrug
daunorubicin hydrochlorideDrug
fludarabine phosphateDrug
gemtuzumab ozogamicinDrug
melphalanDrug
tipifarnibDrug
DNA methylation analysisGenetic
cytogenetic analysisGenetic
gene expression analysisGenetic
mutation analysisGenetic
diagnostic laboratory biomarker analysisOther
immunologic techniqueOther
allogeneic hematopoietic stem cell transplantationProcedure
nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival
- Achievement of complete remission and reasons for failure
- Duration of remission, relapse rates, and deaths
- Hematological and nonhematological toxicity
- Supportive care requirements (and other aspects of health economics)
Locations
96 sites in 1 country. Site status is shown where the registry gives one.
Hereford Hospitals
Hereford, United Kingdom
Wexham Park Hospital
Slough, Berkshire, United Kingdom
Kingston Hospital
Surrey, United Kingdom
Basingstoke and North Hampshire NHS Foundation Trust
Basingstoke, England, United Kingdom
Royal United Hospital
Bath, England, United Kingdom
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
Birmingham, England, United Kingdom
Birmingham Heartlands Hospital
Birmingham, England, United Kingdom
Blackpool Victoria Hospital
Blackpool, England, United Kingdom
Royal Bournemouth Hospital
Bournemouth, England, United Kingdom
Bradford Royal Infirmary
Bradford, England, United Kingdom
Sussex Cancer Centre at Royal Sussex County Hospital
Brighton, England, United Kingdom
Queen's Hospital
Burton-on-Trent, England, United Kingdom
West Suffolk Hospital
Bury St Edmunds, England, United Kingdom
Addenbrooke's Hospital
Cambridge, England, United Kingdom
Kent and Canterbury Hospital
Canterbury, England, United Kingdom
St. Helier Hospital
Carshalton, England, United Kingdom
Gloucestershire Oncology Centre at Cheltenham General Hospital
Cheltenham, England, United Kingdom
Countess of Chester Hospital
Chester, England, United Kingdom
Chesterfield Royal Hospital
Chesterfield, England, United Kingdom
Saint Richards Hospital
Chichester, England, United Kingdom
Walsgrave Hospital
Coventry, England, United Kingdom
Mayday University Hospital
Croydon, England, United Kingdom
Derbyshire Royal Infirmary
Derby, England, United Kingdom
Doncaster Royal Infirmary
Doncaster, England, United Kingdom
Dorset County Hospital
Dorchester, England, United Kingdom
Russells Hall Hospital
Dudley, England, United Kingdom
Royal Devon and Exeter Hospital
Exeter, England, United Kingdom
Medway Maritime Hospital
Gillingham Kent, England, United Kingdom
Harrogate District Hospital
Harrogate, England, United Kingdom
Northwick Park Hospital
Harrow, England, United Kingdom
Hemel Hempstead General
Hemel Hempstead, England, United Kingdom
Wycombe General Hospital
High Wycombe, England, United Kingdom
Hull Royal Infirmary
Hull, England, United Kingdom
Ipswich Hospital
Ipswich, England, United Kingdom
West Middlesex University Hospital
Isleworth, England, United Kingdom
Kettering General Hosptial
Kettering, Northants, England, United Kingdom
Kidderminster Hospital
Kidderminster Worcestershire, England, United Kingdom
Crosshouse Hospital
Kilmarnock, England, United Kingdom
Leeds General Infirmary
Leeds, England, United Kingdom
Leicester Royal Infirmary
Leicester, England, United Kingdom
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.